Analyzing Aptorum Group (NASDAQ:APM) and Spyre Therapeutics (NASDAQ:SYRE)

Spyre Therapeutics (NASDAQ:SYRE) and Aptorum Group (NASDAQ:APM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations.

Volatility and Risk

Spyre Therapeutics has a beta of 2.98, suggesting that its stock price is 198% more volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.

Earnings & Valuation

This table compares Spyre Therapeutics and Aptorum Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890,000.00	1,229.51	-$338.79 million	($4.23)	-4.29
Aptorum Group	$430,000.00	10.60	-$2.83 million	N/A	N/A

Aptorum Group has lower revenue, but higher earnings than Spyre Therapeutics.

Profitability

This table compares Spyre Therapeutics and Aptorum Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-210.01%	-44.40%
Aptorum Group	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Spyre Therapeutics and Aptorum Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	0	0	8	1	3.11
Aptorum Group	0	0	0	0	0.00

Spyre Therapeutics currently has a consensus target price of $50.86, indicating a potential upside of 180.05%. Given Spyre Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Spyre Therapeutics is more favorable than Aptorum Group.

Insider & Institutional Ownership

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Spyre Therapeutics beats Aptorum Group on 8 of the 12 factors compared between the two stocks.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.